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Repeated cycles of infections, caused mainly by Pseudomonas aeruginosa, combined with a robust 
host immune response and tissue injury, determine the course and outcome of cystic fibrosis (CF) 
lung disease. As the disease progresses, P. aeruginosa adapts to the host modifying dramatically 
its phenotype; however, it remains unclear whether and how bacterial adaptive variants and their 
persistence influence the pathogenesis and disease development. Using in vitro and murine models 
of infection, we showed that P. aeruginosa CF-adaptive variants shaped the innate immune response 
favoring their persistence. Next, we refined a murine model of chronic pneumonia extending  
P. aeruginosa infection up to three months. In this model, including CFTR-deficient mice, we unveil 
that the P. aeruginosa persistence lead to CF hallmarks of airway remodelling and fibrosis, including 
epithelial hyperplasia and structure degeneration, goblet cell metaplasia, collagen deposition, elastin 
degradation and several additional markers of tissue damage. This murine model of P. aeruginosa 
chronic infection, reproducing CF lung pathology, will be instrumental to identify novel molecular 
targets and test newly tailored molecules inhibiting chronic inflammation and tissue damage processes 
in pre-clinical studies.
The genetic defect underlying cystic fibrosis (CF) disrupts lung function by obstruction with thick, sticky secre-
tions which predispose to infections, as those by Pseudomonas aeruginosa1. Early in life CF lungs are character-
ized by intermittent airway bacterial infections and excessive neutrophil-dominated inflammation2. Later, chronic 
infection with P. aeruginosa fuels a sustained, exuberant inflammatory response that progressively destroys the 
lungs and ultimately results in respiratory failure. Structural changes in CF lungs include bronchiectasis, air-
way mucus plugging, microabscesses, peribronchial inflammation, fibrosis -associated with increased levels of 
metalloproteinases (MMPs)3–5 and glycosaminoglycans (GAG)6–8- and vascular changes, all indicating extensive 
remodeling that contributes to the lung function decline9–11.
Long-term chronic infection is carried on by P. aeruginosa variants characterized by adaptive traits12,13. Indeed, 
the genetic and phenotypic properties of persisting bacterial cells in CF airways differ greatly from those that ini-
tiated the infections12. The findings that chronic infection in CF patients progresses with bacteria lacking invasive 
virulence functions open the questions whether: i) P. aeruginosa CF-adapted variants live life-long in the lung 
avoiding host immune response and/or ii) their persistence triggers pathways relevant for tissue remodelling, that 
finally lead to lung function decline. These issues are difficult to approach in humans due to confounding factors, 
such as the diverse polymicrobial community, unknown environmental factors and host genetic variability.
Several animal models of P. aeruginosa infection as well as CF mouse models have been generated14. Most of 
them are focused on modelling the acute phases of the P. aeruginosa infection, while others use immobilizing 
agent such as agar, agarose, or seaweed alginate to monitor certain aspects of the chronic infection in mice15. 
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However, at the time of this writing no experimental studies have managed to model the advanced-stage of lung 
pathology that strictly mimics human CF infection14. Pulmonary damage, remodeling and fibrosis are more dif-
ficult to be reproduced. While these pathological traits of human disease can be induced by causative agents 
(e.g. bleomycin), they have not been reproduced following bacterial pneumonia in mice. As a consequence, the 
cascade of events mediated by P. aeruginosa persistence in the pathogenesis of chronic airways infection has been 
difficult to address.
Using models of infection, we demonstrated that P. aeruginosa CF-adapted isolates shape innate immunity to 
favor their persistence. Remarkably, we succeeded in reproducing the advanced stage of chronic infection lasting 
for three months with stable bacterial load and traits of the CF human airway disease in mice, including airway 
remodeling and damage.
Results
P. aeruginosa CF-adapted variants shape the host immune response during the progres-
sion of infection. To track the host response with P. aeruginosa variants, acute (planktonic bacteria) and 
chronic (agar-bead embedded bacteria) infections were established in C57BL/6NCrlBR mice with CF-adapted 
AA43 and AA44 in comparison with AA2 clonal isolate. In particular, AA43 and AA44 were, respectively, 
mucoid and non-mucoid variants with adaptive phenotypes, including absence of swimming motility, low 
twitching motility and production of protease, while AA2 expressed a wide series of virulence factors includ-
ing swimming motility, twitching motility and protease secretion (Fig. S1)16,17. AA2 either disseminated sys-
temically and induced death or was cleared by the host in both acute17 and chronic murine models of lung 
infection confirming previous data16 (Fig. 1A,B). Planktonic bacteria of AA43 and AA44 CF-adapted variants 
were cleared after acute infection17, while bacteria embedded in agar-beads retained their capacity to persist in 
murine lungs. Here, chronic colonization was extended up to three months with bacterial loads stabilizing at 
≈ 104 colony forming units (CFU)/lung. Thus, the susceptibility to P. aeruginosa chronic infection is isolate-de-
pendent in our murine model.
Immunofluorescent staining for P. aeruginosa and Haematoxylin and Eosin (H&E) on day 2 localized the 
infection to bronchial lumens in the agar-beads (Fig. 1C). In the initial phases, infection with the AA43 and 
AA44 CF-adapted variants yielded lower recruitment of innate immune cells, including neutrophil and mac-
rophage (Fig. 2A,B), and less MIP-2, KC, MIP-1α , IL-6, MCP-1 and TNF-α cytokines/chemokines production 
than AA2 (Fig. 3A–F). After 28 and 90 days, the persistent AA43 and AA44 CF-adapted variants, irrespective 
of mucoid phenotype, were localized as macrocolonies in the beads remaining in the bronchial lumen and in 
biofilm-like structures (Fig. 1C). At this stage, cytokines/chemokines decreased further, but were still detectable 
in mice retaining infection with AA43 and AA44 isolates (Fig. 3A–F). The persistence of CF-adapted variants 
promoted an adaptive immune response characterized also by the formation of bronchus-associated lymphoid 
tissue (BALT)-like structures (Fig. 2A,C,D). Overall, P. aeruginosa variants with CF-adapted phenotype deter-
mine a weakening of the innate immune recognition and a shift in the immune response during the course of 
airway diseases.
Differential cell host response to P. aeruginosa phenotypic variants. Next, we conducted in vitro 
analysis to exclude the confounding variables (e.g. different bacterial load) during the course of the infection that 
cannot be controlled in mouse models. Thus, RNA macroarray analysis18 of human IB3-1 cells infected with AA2 
and CF-adapted AA43 and AA44 variants was performed to investigate the host response mediated by bronchial 
epithelial cell models widely investigated in CF inflammation. We identified a total of 20 genes whose transcrip-
tion was changed more than 2-fold in cells infected with different P. aeruginosa variants but with equal bacterial 
load (Fig. 4A, Table S1). Only five genes were up-regulated after infection with the AA43 and AA44 CF-adapted 
variants in respect to AA2 infection, while the majority (15 out of 20) were down-regulated, including several 
chemokines and cytokines and their receptors (TNF-α , Gro-β and γ , IP-10, IL-8, FPR2, CCR6, CCR7, CCR9), 
and adhesion molecules involved in the process of leukocytes extravasation and recruitment (VCAM-1 and 
ICAM-1). In addition, although AA2 isolate induced higher expression of elastase 2, liable for collagen-IV and 
elastin proteolysis, AA43 and AA44 induced much higher expression of the matrix metalloprotease 9 (MMP-9), 
suggesting a contribution of P. aeruginosa CF-adapted variants in matrix degradation. Validation of results by real 
time PCR and/or ELISA for selected targets (IL-8, TNF-α , IP-10, VCAM-1, ICAM-1, Gro-β , MMP-9) has been 
carried out in different cell types (IB3-1, C38 and THP-1) (Fig. 4B–I).
Next, we extended our investigation to additional P. aeruginosa CF-adaptive variants (Fig. 4B–H). Selection 
was based on previous characterization: KK71 and KK72 showed phenotypic traits of CF-adaptation absent 
in KK1 and KK2 clonal variants (Fig. S1)16,17. Results confirmed the lower pro-inflammatory potential of 
CF-adapted KK71 and KK72 in comparison with KK1 and KK2 variants. Overall, these results unravel that 
P. aeruginosa CF-adapted variants rewrite the host response in CF bronchial epithelial cell lines and in particular 
attenuate the expression of a set of genes involved in inflammation, confirming our hypothesis with additional 
P. aeruginosa variants.
P. aeruginosa persistence promotes airway tissue damage in mice that mirrors human 
CF pathology. Next, we investigated whether and to what extent chronic persistence by P. aeruginosa 
CF-adapted variants recapitulates human CF lung disease (Fig. 5). Mice, retaining infection with AA43 and 
AA44 CF-adapted variants for one month, displayed hallmarks of CF chronic lung pathology: intraluminal and 
peribronchial inflammation, epithelial hyperplasia and structure degeneration, goblet cell metaplasia, collagen 
deposition and elastin degradation (Fig. 5A–C). Biochemical markers of tissue damage in CF disease such 
as MMP-9 activity and protein, TGF-β 1 protein and sulphated GAG (sGAG) increased progressively during 
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long-term infection with AA43 and AA44 CF-adapted variants (Fig. 6A–F). So for the first time, the above 
described mouse model of long-term airway chronic infection established with P. aeruginosa CF-adapted var-
iants reproduced several traits of human CF lung pathology.
Figure 1. Virulence of P. aeruginosa isolates and bacterial localization in murine models of airways 
infection. Two groups of minimum five C57Bl/6NCrlBR mice were infected with 5 × 106 CFU/lung of 
planktonic bacteria for the acute infection (data modified from Fig. 5P included in Lorè NI et al. PLoS One 
2012;7(4):e35648.) and with 1 to 2 × 106 CFU/lung of isolates embedded in agar beads for the chronic infection 
and analyzed during a time course post-infection (12 hours, 1 and 2 days of acute infection and 2, 14, 28 and 90 
days of chronic lung infection). (A) CFUs were evaluated in total lung. Dots represent CFUs in individual mice 
and horizontal lines represent median values. The data are pooled from at least two independent experiments 
(n = 1–9). Statistical significance is indicated: *p < 0.05, **p < 0.01, ***p < 0.001. (B) The incidences of 
mortality induced by bacteremia (red), clearance (white) and airway infection (green) were determined. The 
data are pooled from at least two independent experiments (n = 8–24). (C) Bacterial and agar-beads localization 
in the lung were evaluated on challenged mice by immunofluorescence (with specific antibody against  
P. aeruginosa, stained in red, and with 4,6-Diamidino-2-phenylindole dihydrochloride, stained in blue) and 
H&E staining. Scale bar: 25 μ m.
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Taking into consideration the emerging relevance of MMPs to pulmonary remodelling and impaired lung 
function in CF patients6,19,20, and MMP-9 activation in our chronic infection model and cell culture, we investi-
gated host response to chronic infection by AA43 CF-adapted isolate in MMP-9 deficient mice. Lower collagen 
levels were found in Mmp-9−/− mice compared to the isogenic counterpart (Fig. 6G) while no differences in terms 
of bacterial load, inflammatory cells recruitment, sGAG and TGF-β 1 after one month were recorded (Fig. S2). 
These findings suggest a role of MMP-9 in the process of collagen deposition during P. aeruginosa chronic 
persistence.
Contribution of CFTR-deficiency to the pathogenesis of P. aeruginosa infection. To deter-
mine whether the CFTR-deficiency could exacerbate the inflammatory response or tissue damage after chronic 
P. aeruginosa infection, we infected gut-corrected CFTR-deficient [C57Bl/6 Cftrtm1UNCTgN(FABPCFTR)#Jaw] 
and their congenic wt mice with the AA43 CF-adapted variant. The percentage of P. aeruginosa infection and 
bacterial load were similar between CF and wt mice, revealing the capacity of P. aeruginosa AA43 CF-adapted 
isolate to persist in murine lungs regardless of the CF genetic background (Fig. 7A,B). However, at the early time 
point the inflammatory response following P. aeruginosa infection in the bronchoalveolar lavage fluid (BALF) 
was higher in CF mice, in terms of total cells, neutrophils, macrophages and MIP-2 levels, compared to wt mice 
(Fig. 7C–F). KC, MIP-1α , IL-6, MCP-1 and TNF-α in BALF were similar between CF and isogenic wt mice 
(Fig. 7G–K). The chronic BALF response was similar in CF and wt animals. In the lung homogenate, the levels 
of all of the above-mentioned chemokines/cytokines were similar between CF and wt mice at both the early and 
late chronic time points. At an advanced stage of chronic infection, CF and wt mice differed in terms of goblet cell 
metaplasia. Histology and pathological scores revealed a higher number of goblet cells in the lung tissue of CF 
Figure 2. Lung histology and histopathological score of immune cells recruitment in the murine model 
of P. aeruginosa chronic airways infection. C57Bl/6NCrlBR mice were infected with 1 to 2 × 106 CFU/lung 
of isolates embedded in agar beads for the chronic infection and analyzed during a time course post-infection 
(2, 28 and 90 days). (A) Lung histopathology was performed on challenged mice by H&E staining. Scale bars: 
200 μ m. BALT-like structures are indicated by asterisks. Innate (B) and adaptive (C) immune cells infiltration 
and BALT activation (D) were scored in tissue section of murine lungs stained with H&E. The data are pooled 
from at least two independent experiments (n = 2–7). Values represent the mean ± standard error of the mean 
(SEM). Statistical significance is indicated: *p < 0.05, **p < 0.01.
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mice compared to wt, indicating greater mucus production (Figs 7L and S3A). Other markers of tissue damage, 
such as collagen deposition, elastin degradation, MMP-9 activity, sGAG and TGF-β 1, were similarly increased in 
CF and wt mice (Fig. S3B–F). Furthermore, no differences were detected in recruitment of innate and adaptive 
immune cells, and BALT formation (data not shown). Overall, these data indicate that, in mice, alteration of the 
immune response and subsequent tissue remodeling during P. aeruginosa chronic infection are mostly independ-
ent of the presence of functional CFTR.
Discussion
Current debates on CF pathogenesis recognize that multifactorial variables contribute to the outcome of lung 
disease; these include host factors and the bacterial pathogenic potential21,22. Dissection of these factors and 
their causal associations in humans are complicated by confounding variables that cannot be controlled indi-
vidually. Here, using well established in vitro and in vivo models of infection we demonstrated that P. aerugi-
nosa CF-adapted variants shape the innate immune response to favor their persistence. However, the previous 
lack of a suitable animal model of long-term chronic infection has limited understanding of the consequence of 
P. aeruginosa persistence on host response. In this study, we refined the agar-beads mouse model approaching 
the advanced stage of chronic pneumonia. This model was instrumental in demonstrating the contribution of 
P. aeruginosa long-term persistence in activating relevant pathways for tissue remodeling and damage. 
Surprisingly, P. aeruginosa persistence had a greater effect on inflammation and damage profile rather than the 
Cftr mutation itself. These findings have real importance to understanding CF airways disease pathogenesis and 
progression.
For this study, we used P. aeruginosa isolates sampled at the onset of infection and after years of chronic 
colonization; they were selected for their diversity determined in previous characterization16,17,23. The P. aerugi-
nosa CF-adapted isolates were genetically characterized by genome rearrangements, mutations, and variations in 
pathogenic islands, and phenotypically by altered motility, mucoidy, and changes in virulence factors. Thus, the 
selected P. aeruginosa isolates display features commonly associated with bacterial adaptation to CF lung12,13,16. 
When we investigated P. aeruginosa/host interaction in mice, the P. aeruginosa isolate equipped with virulence 
factors either disseminated systemically resulting in death or was cleared by a strong host inflammatory response, 
while CF-adapted variants diminished the innate immune response to allow long-term persistence. Indeed, by 
measuring cytokines/chemokines at acute/early phases of infection, we found lower pro-inflammatory response 
induced by P. aeruginosa adapted variants. One factor of major interest was that the host response of P. aeruginosa 
adapted variants did not appear to be dependent only on a particular bacterial phenotype or clonal variants. 
Different P. aeruginosa patho-adaptive variants (e.g. mucoid and a non-mucoid) or belonging to different patients, 
showed a similar capacity to shape the host immune response.
Figure 3. Cytokines/chemokines profiles in murine models after P. aeruginosa infection. C57Bl/6NCrlBR 
mice were infected with 5 × 106 CFU/lung of planktonic bacteria for the acute infection or 1 to 2 × 106 CFU/lung 
of strains embedded in agar beads for the chronic infection and analyzed during a time course post-infection  
(12 hours and 1 day of acute infection and 2, 14 and 28 days of chronic lung infection). Cytokines and chemokines, 
including MIP-2 (A), KC (B), MIP-1α (C), IL-6 (D), MCP-1 (E) and TNF-α (F), were measured by Bioplex in 
lung homogenates. The data are pooled from at least two independent experiments (n = 3–6). Values represent the 
mean ± SEM. Statistical significance is indicated: *P < 0.05, **P < 0.01.
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Although mice deficient for Cftr24, or overexpressing the β -ENaC channel25, have been available for many 
years, these models do not completely mimic the advanced human pathology26–29. Infection of CF mice with 
P. aeruginosa has been performed and resulted in a heightened inflammatory response30, but high mortality or 
resolution of the infection have typically limited pathogen persistence for long time. Lung pathology in β -ENaC 
mice reflects undeniably several hallmarks of CF airways disease, including mucus hyperproduction, goblet cells 
metaplasia, neutrophilic inflammation and poor bacterial clearance31,32. However, they do not reproduce sponta-
neously the advanced stage of CF lung disease, including chronic P. aeruginosa infection, the development of the 
adaptive immune response and a considerable tissue damage (e.g. elastin degradation and collagen deposition). 
Models of chronic infections have been described but, at the time of writing, no experimental studies have man-
aged to achieve the progressive advanced-stage of lung pathology induced by chronic bacterial colonization that 
Figure 4. Expression/release of markers of inflammation and tissue damage in cell lines after infection 
with P. aeruginosa phenotypic variants. Bronchial epithelial CF cells IB3-1 were infected for 4 hours with  
P. aeruginosa AA2-AA43-AA44 isolates, RNA extracted and retrotranscribed, and macroarray conducted.  
(A) Genes expression is expressed after normalization on expression induced by AA2. Validation of gene 
expression was performed by real time PCR in IB3-1 (B,D–H) and isogenic non-CF cells C38 (B,D) after 
infection with AA2, AA43, AA44, KK1, KK2, KK71 and KK72. (C) Validation of IL-8 protein release was 
performed by ELISA in culture medium of IB3-1 and C38 after infection with isolates mentioned above.  
(I) Macrophagic-like cells THP-1 were infected for with P. aeruginosa AA2, AA43 and AA44 isolates (MOI 1), 
and MMP-9 release was measured in the culture supernatants by ELISA. Values represent the mean ± SEM. 
The data are pooled from at least three independent experiments. Statistical significance is indicated: *p < 0.05, 
**p < 0.01.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:21465 | DOI: 10.1038/srep21465
strictly mimics human CF infection (e.g., chronic Pseudomonal endobronchitis). Although models of long-term 
chronic infection have been described and are undeniably useful to study several features of CF lung disease 
including P. aeruginosa evolution or chronic inflammation, they show some weaknesses, such as the absence of a 
stable bacterial load over the course of the infection or the use of mechanical devices as catheters that render, the 
model not-physiological33,34. The previous lack of an accessible CF animal model has limited not only a satisfac-
tory evaluation of the host adaptive immune response, but also the understanding of tissue damage and remod-
eling processes observed during chronic pneumonia, as described in CF disease15,35. We successfully reproduced 
the long-term chronic infection with stable bacterial titers up to three months and the presence of bacteria in 
Figure 5. Lung histology and histopathological score of tissue damage in murine lung after infection 
with P. aeruginosa. C57Bl/6NCrlBR mice were infected with 1 to 2 × 106 CFU/lung of isolates embedded in 
agar beads and analyzed 28 days post-infection. Sections of airways from transplanted CF patients and from 
C57Bl/6NCrlBR infected with CF-adapted isolates AA43 and AA44 and sterile beads were stained with H&E, 
MTS for collagen, VEG for elastic fibers and AB/PAS for mucopolysaccarides, according to the standard 
procedures (A). Scale bars: 12.5 μ m for H&E, 25 μ m for MTS, VEG and AB-PAS. Scorings of bronchial 
epithelial degeneration, collagen deposition and elastin degradation (B) were performed on slices stained with 
H&E, MTS and VEG, respectively. Goblet cells numbers were evaluated on slices stained with AB-PAS (C). 
The data are pooled from at least two independent experiments (n = 2–6). Values represent the mean ± SEM. 
Statistical significance is indicated: *p < 0.05.
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biofilm-like structures. In this model, a long-term consequence of P. aeruginosa chronic infection is the formation 
of BALT-like structures. Moreover, the degeneration of the epithelial structure, collagen deposition, elastin deg-
radation, increased factors associated with matrix remodeling (MMP-9 activity, sGAG and TGF-β 1) and goblet 
cell metaplasia were also observed in murine airways. This immunopathology is notably similar to the clinical 
descriptions of human CF lung disease, mirroring chronic Pseudomonal endobronchitis of the CF population.
In our CF mouse model, we found that the CFTR deficiency was associated with a higher inflammatory 
response to P. aeruginosa at the early phases of infection which is in agreement with previous observations15. 
When we extended the infection to the advanced stage, tissue remodeling and damage were partially inde-
pendent of the Cftr murine background. Interestingly, our data showed that pathological traits developed sim-
ilarly in both wt and CF mice, with further increase of goblet cell metaplasia in the CF host. In this context, the 
pro-inflammatory environment of the lung can impair and decrease CFTR function as demonstrated in chronic 
obstructive pulmonary disease (COPD)36,37. Furthermore, recent observations indicate that TGF-β 1 and hypoxic 
environments down-regulate the expression and activity of CFTR38,39. Thus, it could be speculated that chronic 
inflammatory profile and high levels of TGF-β 1 after long-term P. aeruginosa infection in wt mice may undermine 
CFTR function and dampen the differences between wt and CF mice. Further studies are required to strengthen 
these hypotheses. Most important, the findings that CFTR function could be impaired by P. aeruginosa infec-
tion, its virulence factors and the associated-chronic inflammation40 may further explain the similar patholog-
ical events developed independently of the CFTR deficiency in our murine model. Overall our data strongly 
suggest that P. aeruginosa persistence is a key driver of the pathogenesis of CF chronic lung disease. Relevance 
of these studies may be extended to other chronic endobronchitis including advanced COPD, where some hall-
marks observed in CF, such as high inflammation, tissue remodeling and P. aeruginosa persistence, have been 
described41.
New therapeutic approaches to preserve airway structure and pulmonary function are a clinical need. Taking 
into consideration the emerging relevance of MMPs to pulmonary remodelling in CF patients6,19,20 and MMP-9 
link to P. aeruginosa persistence, observed in this work, we further investigated its role in the pathophysiology 
of the chronic disease. Results obtained in Mmp-9−/− mice demonstrated that this metalloprotease contributes 
to collagen deposition during P. aeruginosa chronic infection, while it does not exert any harmful effect on host 
defense. In agreement with other recent studies42, our results may support the exploitation of this target in CF.
In conclusion, our study demonstrates that P. aeruginosa CF-adaptive variants shape the host response favor-
ing their persistence within the lung. Furthermore, the P. aeruginosa persistence contributes to modulate path-
ways relevant for airway structural changes, reproducing human pathology in mice. Notably, the mouse model, 
refined in this study, is an invaluable tool for studying the pathogenesis and progression of infection in CF and 
other chronic airway diseases (such as advanced COPD) and may be an ideal platform for testing novel ther-
apies. In addition, our findings emphasize that the development of new therapeutic interventions (e.g., drug/
Figure 6. Tissue damage markers, including MMP-9, in murine models after P. aeruginosa infection. 
C57Bl/6NCrlBR mice were infected with 1 to 2 × 106 CFU/lung of CF-adapted isolates embedded in agar beads 
for 14 and 28 days. Levels of MMP-9 protein (A) in BALF by ELISA, MMP-9 activity (B) in BALF and  
(C) lung homogenate by zymography, TGF-β 1 (D) in BALF and (E) lung homogenate by Bioplex and sGAG  
(F) in lung homogenate by a dye-binding colorimetric assay were measured after 14 and 28 days of chronic lung 
infection. Values represent the mean ± SEM. The data are pooled from at least two independent experiments 
(n = 3–12). G) B6.FVB(Cg)-Mmp9tm1Tvu/J and congenic mice were infected with 2 × 106 CFU/lung of AA43 
strain embedded in agar beads. Collagen levels were evaluated by a dye-binding assay in lung homogenate after 
28 days of chronic lung infection with the P. aeruginosa CF-adapted isolate AA43. Values are represented as 
mean ± SEM. The data derive from one experiment (n = 6–7). Statistical significance is indicated: *p < 0.05, 
**p < 0.01.
www.nature.com/scientificreports/
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pharmacological) for CF should target tissue remodeling and damage and account for immune changes that 
manifest in the setting of chronic infection.
Methods
Ethics Statement. Animal studies were conducted according to protocols adhering strictly to the Italian 
Ministry of Health guidelines for the use and care of experimental animals (IACUC protocols #402 and 502) and 
approved by the San Raffaele Scientific Institute (Milan, Italy) Institutional Animal Care and Use Committee 
(IACUC).
The use of human bronchi, obtained from patients undergoing lung transplant, was approved by the Ethical 
Committee of the Gaslini Institute (Genova, Italy), in accordance with the guidelines of the Italian Ministry of 
Health. Each patient provided written informed consent to the study using a form that was also approved by the 
Ethical Committee (approval #13).
Figure 7. Bacterial virulence and lung inflammatory response in CF and congenic wt mice after  
P. aeruginosa chronic lung infection. Gut-corrected CFTR-deficient C57Bl/6 Cftrtm1UNCTgN(FABPCFTR)#Jaw 
and congenic wt mice were infected with 2 × 106 CFU/lung of P. aeruginosa AA43 strain embedded in 
agar beads and analyzed after 2 and 28 Days. A) The incidences of mortality induced by bacteremia (red), 
clearance (white) and airway infection (green) were determined. The data are pooled from two independent 
experiments (n = 8–28). B) CFU were evaluated in total lung. Dots represent individual mice measurements 
and horizontal lines represent the median values reported in a log scale (n = 8–11). The number of total cells 
(C) and in particular of neutrophils (D) and macrophages (E) in the airways were analyzed in BALF of mice. 
Cytokines/chemokines, including MIP-2 (F), MIP-1α (G), KC (H), IL-6 (I), MCP-1 (J) and TNF-α (K), were 
measured by Bioplex in murine BALF (left side of the graph) and lung homogenates (right side of the graph). 
Sections of murine lungs infected with AA43 for 28 days were stained with AB/PAS for mucopolysaccharides, 
according to the standard procedure. Goblet cells numbers were evaluated on slices stained with AB-PAS (L). 
Values represent the mean ± SEM. The data are pooled from at least two independent experiments (n = 3–11). 
Statistical significance is indicated: *p < 0.05, **p < 0.01, ***p < 0.001.
www.nature.com/scientificreports/
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Research with the longitudinal bacterial isolates from CF individuals (AA2, AA43, AA44, KK1, KK2, KK71 
and KK72), used for in vitro and animal experiments, has been approved by the Ethics Commission of Hannover 
Medical School, Germany. The patients and parents gave informed consent before the sample collection. Approval 
for storing of biological materials was obtained by the Ethics Commission of Hannover Medical School, Germany.
Bacterial strains. Sequential P. aeruginosa isolates from CF patients were chosen from a strain collection, 
previously characterized for genotypic and phenotypic traits, and virulence16,17,23. AA2, KK1 and KK2, expressing 
virulence factors, were isolated at the onset of chronic infection, while AA43, AA44, KK71 and KK72, showing 
different adaptive phenotypes, including mucoidy for AA43, were collected after 7 to 13 years after colonization.
Mouse strains. C57Bl/6 (C57Bl/6NCrlBR, Charles River), MMP-9−/− (B6.FVB(Cg)-Mmp9tm1Tvu/J, 
Jackson Laboratory) and congenic mice (C57Bl/6J, Jackson Laboratory), 8 to 10 weeks old, and CF [gut-corrected 
CFTR-deficient C57Bl/6 Cftrtm1UNCTgN(FABPCFTR)#Jaw] and congenic wild-type (wt) mice (originally obtained 
from Case Western Reserve University and maintained at San Raffaele Scientific Institute, Milan, Italy)43, 11 to 16 
weeks old, were maintained in specific pathogen-free conditions.
Mouse model of acute and chronic P. aeruginosa infection. Mice were injected intratracheally with 
5 × 106 CFU of planktonic P. aeruginosa or with 1–2 × 106 CFU, embedded in agar beads, following established 
procedures16,17,44. The bacterial load was previously set-up as the minimum inoculum to establish chronic infec-
tion45. BALF and lung were recovered and processed, as previously described44.
Histological examination. Sections of murine and human lungs for histological analysis were collected 
and stained by Haematoxylin and Eosin (H&E), Acid Schiff (AB-PAS), Masson’s trichrome (MTS), Verhoeff ’s 
elastic (VEG) and immunofluorescence (IF) stainings and were examined blindly and scored by a pathologist, as 
detailed in Supplementary Information.
Cell lines. IB3-1 cells, an adeno-associated virus-transformed human bronchial epithelial cell line derived 
from a CF patient (Δ F508/W1282X), and C38 cells, the cell line which expresses a plasmid encoding func-
tional CFTR, and non-adherent human myelomonocytic THP1 cells were obtained from LGC Promochem. 
IB3-1 cells were grown as previously described17. In vitro infection was performed as described in Supplementary 
Information.
Macroarray analysis. Macroarray analysis was performed by using TaqMan Low Density Array (TLDA) 
platform (Applied Biosystems, Foster City, CA), as detailed in Supplementary Information.
Evaluation of Cytokines/chemokines and markers associated to tissue damage. Cytokines/
chemokines and growth factors, MMP-9 active levels, sGAG and collagen, and MMP-9 activity were respectively 
measured by Bioplex, ELISA, colorimetric dye-binding assay and zymography, according to the manufacturer’s 
instructions as detailed in Supplementary Information.
Statistics. Data analysis was performed using a nonparametric two-taled Mann-Whitney U test for single 
comparison when comparing data induced by a specific strain at two time points during acute infection (e.g. 
cytokines/chemokines levels) or comparison of data from wt and CF mice at each time-point. To compare data 
induced by CF-adapted variants to AA2 or Ctrl data at one time-point and data induced by a specific strain across 
multiple time-points a nonparametric Kruskal-Wallis test was used followed by post-hoc Dunn test to correct for 
multiple comparisons. Mortality and percentage of infection were compared using Fisher exact test. P < 0.05 was 
considered significant.
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